Please assess the completion status of the following clinical trial:

Trial Title: Parallel Arm Trial of AD109 and AD504 In Patients With OSA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 to 65 years of age for men and 18-75 for women, inclusive, at the Screening Visit.~* Mean AHI 10 to 45 events/h, inclusive~* PGI-S: \>1~Exclusion Criteria:~* Current clinically significant sleep disorder other than OSA~* Clinically significant craniofacial malformation.~* Clinically significant cardiac disease (e.g. rhythm disturbances, coronary artery disease or heart failure or hypertension requiring more than 2 medications for control).~* Participants with a history of using devices for OSA treatment, including CPAP, oral or nasal devices, or positional devices, may enroll as long as the devices have not been used for at least 2 weeks prior to first PSG and are not used during participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AD109 Dose 1 (Type: EXPERIMENTAL): None
- AD109 Dose 2 (Type: EXPERIMENTAL): None
- AD504 Dose 1 (Type: EXPERIMENTAL): None
- AD504 Dose 2 (Type: EXPERIMENTAL): None
- Atomoxetine 1 (Type: ACTIVE_COMPARATOR): None
- Atomoxetine 2 (Type: ACTIVE_COMPARATOR): None
- Placebo 1 (Type: PLACEBO_COMPARATOR): None
- Placebo 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).